生物制剂-话题@MedSci

#生物制剂#

122篇内容 | 2599人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1826026, encodeId=de8c18260267f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=全球治疗系统性红斑狼疮（SLE）创新双靶生物制剂泰它西普在华率先上市！, objectType=article, longId=209847, objectId=5a7020984efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a7020984efa, replyNumber=0, likeNumber=57, createdTime=2021-12-22, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a7020984efa, moduleTitle=全球治疗系统性红斑狼疮（SLE）创新双靶生物制剂泰它西普在华率先上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a7020984efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826025, encodeId=eefc1826025db, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Gastroenterology：炎症性肠病的妇女接受生物制剂和硫唑嘌呤治疗对于新生儿结局的影响, objectType=article, longId=208686, objectId=ab162086862b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab162086862b, replyNumber=0, likeNumber=40, createdTime=2021-06-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab162086862b, moduleTitle=Gastroenterology：炎症性肠病的妇女接受生物制剂和硫唑嘌呤治疗对于新生儿结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab162086862b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826030, encodeId=0fdb18260302e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=生物制剂治疗干燥综合征效果如何?该怎么选择？, objectType=article, longId=218306, objectId=b0cd21830665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0cd21830665, replyNumber=0, likeNumber=25, createdTime=2022-05-16, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0cd21830665, moduleTitle=生物制剂治疗干燥综合征效果如何?该怎么选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0cd21830665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826039, encodeId=eb95182603986, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=IBD: 生物制剂诱导治疗后的疾病活动可以预测克罗恩病和溃疡性结肠炎的短期结果, objectType=article, longId=293661, objectId=59ed2936613a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ed2936613a, replyNumber=0, likeNumber=41, createdTime=2022-10-01, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ed2936613a, moduleTitle=IBD: 生物制剂诱导治疗后的疾病活动可以预测克罗恩病和溃疡性结肠炎的短期结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ed2936613a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826028, encodeId=5edd182602816, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=AP&T:与抗TNF生物制剂相比，乌司奴单抗治疗克罗恩病和维多珠单抗治疗溃疡性结肠炎的优越更好, objectType=article, longId=214301, objectId=6c24214301c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c24214301c9, replyNumber=0, likeNumber=39, createdTime=2022-06-10, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c24214301c9, moduleTitle=AP&T:与抗TNF生物制剂相比，乌司奴单抗治疗克罗恩病和维多珠单抗治疗溃疡性结肠炎的优越更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c24214301c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826024, encodeId=b3801826024af, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=治疗类风湿关节炎和强直性脊柱炎的生物制剂进入国家医保目录, objectType=article, longId=208008, objectId=22a520800864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a520800864, replyNumber=0, likeNumber=42, createdTime=2021-06-26, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a520800864, moduleTitle=治疗类风湿关节炎和强直性脊柱炎的生物制剂进入国家医保目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22a520800864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826023, encodeId=85cd182602354, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=JCC: 生物制剂疗法对于IBD患者患有SARS-CoV2阳性的概率的影响, objectType=article, longId=203627, objectId=e64f20362e03, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64f20362e03, replyNumber=0, likeNumber=28, createdTime=2021-04-17, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64f20362e03, moduleTitle=JCC: 生物制剂疗法对于IBD患者患有SARS-CoV2阳性的概率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e64f20362e03)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826021, encodeId=473f18260211a, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=UEGW 2020：更换其他类型的生物制剂或其他抗TNF抗体，是应对抗药性抗体更有效的策略, objectType=article, longId=202201, objectId=a6482022014c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6482022014c, replyNumber=0, likeNumber=26, createdTime=2020-10-29, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6482022014c, moduleTitle=UEGW 2020：更换其他类型的生物制剂或其他抗TNF抗体，是应对抗药性抗体更有效的策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6482022014c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826027, encodeId=5372182602e4a, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=BioDrugs：生物制剂在治疗强直性脊柱炎中的药物用药率如何？, objectType=article, longId=210771, objectId=1bf4210e71a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf4210e71a3, replyNumber=0, likeNumber=27, createdTime=2021-06-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf4210e71a3, moduleTitle=BioDrugs：生物制剂在治疗强直性脊柱炎中的药物用药率如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bf4210e71a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826014, encodeId=f5511826014a3, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195932, objectId=08a71959323d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a71959323d, replyNumber=0, likeNumber=14, createdTime=2020-11-29, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a71959323d, moduleTitle=实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a71959323d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826020, encodeId=915a182602036, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Clin Gastroenterology H: 患过恶性肿瘤的患者接受生物制剂治疗并不会增加肿瘤复发风险, objectType=article, longId=202136, objectId=0370202136f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0370202136f7, replyNumber=0, likeNumber=38, createdTime=2021-03-26, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0370202136f7, moduleTitle=Clin Gastroenterology H: 患过恶性肿瘤的患者接受生物制剂治疗并不会增加肿瘤复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0370202136f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826022, encodeId=7e951826022e6, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=全球且**！GSK生物制剂*倍力腾（化学名：贝利尤单抗）二度参展进博会，为系统性红斑狼疮儿童患者带来希望, objectType=article, longId=203030, objectId=584520303009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=584520303009, replyNumber=0, likeNumber=34, createdTime=2021-05-05, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=584520303009, moduleTitle=全球且**！GSK生物制剂*倍力腾（化学名：贝利尤单抗）二度参展进博会，为系统性红斑狼疮儿童患者带来希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=584520303009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826044, encodeId=f2771826044c4, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Semin Arthritis Rheu：类风湿性关节炎中与羟氯喹、甲氨蝶呤、生物制剂和糖皮质激素相关的糖尿病, objectType=article, longId=194465, objectId=ed1b19446564, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed1b19446564, replyNumber=0, likeNumber=64, createdTime=2020-12-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed1b19446564, moduleTitle=Semin Arthritis Rheu：类风湿性关节炎中与羟氯喹、甲氨蝶呤、生物制剂和糖皮质激素相关的糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed1b19446564)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826018, encodeId=9fca1826018f3, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=IBD: 儿童克罗恩病患者诊断时的脂肪抵抗素水平可预测生物制剂的治疗效果, objectType=article, longId=201953, objectId=cd1620195340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd1620195340, replyNumber=0, likeNumber=41, createdTime=2021-05-07, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd1620195340, moduleTitle=IBD: 儿童克罗恩病患者诊断时的脂肪抵抗素水平可预测生物制剂的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd1620195340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826015, encodeId=b79318260154f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195933, objectId=588919593321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=588919593321, replyNumber=0, likeNumber=31, createdTime=2021-04-09, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=588919593321, moduleTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=588919593321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826010, encodeId=a5dd1826010ba, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=**肠道选择性生物制剂安吉优®（注射用维得利珠单抗）获批进入中国，为炎症性肠病患者带来曙光, objectType=article, longId=190010, objectId=9ca0190010fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ca0190010fb, replyNumber=0, likeNumber=39, createdTime=2020-11-23, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ca0190010fb, moduleTitle=**肠道选择性生物制剂安吉优®（注射用维得利珠单抗）获批进入中国，为炎症性肠病患者带来曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ca0190010fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826019, encodeId=ff1a18260194c, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Clin Gastroenterology H: 炎性肠病患者接受生物制剂治疗后肠道切除的概率明显降低, objectType=article, longId=202135, objectId=0f3f2021356e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3f2021356e, replyNumber=0, likeNumber=42, createdTime=2021-01-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3f2021356e, moduleTitle=Clin Gastroenterology H: 炎性肠病患者接受生物制剂治疗后肠道切除的概率明显降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3f2021356e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826012, encodeId=2b5f182601279, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=Arthritis Rheumatol：生物制剂可以预防类风湿性关节炎的心血管事件, objectType=article, longId=193034, objectId=dcc4193034d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc4193034d4, replyNumber=0, likeNumber=42, createdTime=2021-02-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc4193034d4, moduleTitle=Arthritis Rheumatol：生物制剂可以预防类风湿性关节炎的心血管事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcc4193034d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826017, encodeId=30d3182601e3e, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法，可减少与炎症性肠病相关并发症的风险, objectType=article, longId=201872, objectId=a9822018e210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9822018e210, replyNumber=0, likeNumber=33, createdTime=2020-11-16, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9822018e210, moduleTitle=JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法，可减少与炎症性肠病相关并发症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9822018e210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1826016, encodeId=c5f71826016d5, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, objectTitle=IBD:上皮细胞生物标记物可预测克罗恩病对生物制剂的反应, objectType=article, longId=201202, objectId=ad17201202da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad17201202da, replyNumber=0, likeNumber=43, createdTime=2021-07-13, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad17201202da, moduleTitle=IBD:上皮细胞生物标记物可预测克罗恩病对生物制剂的反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad17201202da)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生物制剂

2020-05-29发表于威斯康星

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

全球治疗系统性红斑狼疮（SLE）创新双靶生物制剂泰它西普在华率先上市！

2021-12-22

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

Gastroenterology：炎症性肠病的妇女接受生物制剂和硫唑嘌呤治疗对于新生儿结局的影响

2021-06-30

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

生物制剂治疗干燥综合征效果如何?该怎么选择？

2022-05-16

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

IBD: 生物制剂诱导治疗后的疾病活动可以预测克罗恩病和溃疡性结肠炎的短期结果

2022-10-01

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

AP&T:与抗TNF生物制剂相比，乌司奴单抗治疗克罗恩病和维多珠单抗治疗溃疡性结肠炎的优越更好

2022-06-10

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

治疗类风湿关节炎和强直性脊柱炎的生物制剂进入国家医保目录

2021-06-26

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

JCC: 生物制剂疗法对于IBD患者患有SARS-CoV2阳性的概率的影响

2021-04-17

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

UEGW 2020：更换其他类型的生物制剂或其他抗TNF抗体，是应对抗药性抗体更有效的策略

2020-10-29

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

BioDrugs：生物制剂在治疗强直性脊柱炎中的药物用药率如何？

2021-06-18

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

实验性生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-11-29

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

Clin Gastroenterology H: 患过恶性肿瘤的患者接受生物制剂治疗并不会增加肿瘤复发风险

2021-03-26

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

全球且**！GSK生物制剂*倍力腾（化学名：贝利尤单抗）二度参展进博会，为系统性红斑狼疮儿童患者带来希望

2021-05-05

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

Semin Arthritis Rheu：类风湿性关节炎中与羟氯喹、甲氨蝶呤、生物制剂和糖皮质激素相关的糖尿病

2020-12-18

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

IBD: 儿童克罗恩病患者诊断时的脂肪抵抗素水平可预测生物制剂的治疗效果

2021-05-07

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2021-04-09

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

**肠道选择性生物制剂安吉优®（注射用维得利珠单抗）获批进入中国，为炎症性肠病患者带来曙光

2020-11-23

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

Clin Gastroenterology H: 炎性肠病患者接受生物制剂治疗后肠道切除的概率明显降低

2021-01-30

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

Arthritis Rheumatol：生物制剂可以预防类风湿性关节炎的心血管事件

2021-02-02

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法，可减少与炎症性肠病相关并发症的风险

2020-11-16

一叶知秋 (审核中...)

前往app查看评论内容

#生物制剂#

IBD:上皮细胞生物标记物可预测克罗恩病对生物制剂的反应

2021-07-13

科室
- - 订阅+
  - 更多科室
工具
服务